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ABSTRACT

The emergence of SARS-CoV-2 has resulted in an ongoing global pandemic with signiﬁcant morbidity, mortality, and
economic consequences. The susceptibility of diﬀerent animal species to SARS-CoV-2 is of concern due to the potential
for interspecies transmission, and the requirement for pre-clinical animal models to develop eﬀective countermeasures. In
the current study, we determined the ability of SARS-CoV-2 to (i) replicate in porcine cell lines, (ii) establish infection in
domestic pigs via experimental oral/intranasal/intratracheal inoculation, and (iii) transmit to co-housed naïve sentinel pigs.
SARS-CoV-2 was able to replicate in two diﬀerent porcine cell lines with cytopathic eﬀects. Interestingly, none of the
SARS-CoV-2-inoculated pigs showed evidence of clinical signs, viral replication or SARS-CoV-2-speciﬁc antibody responses.
Moreover, none of the sentinel pigs displayed markers of SARS-CoV-2 infection. These data indicate that although
diﬀerent porcine cell lines are permissive to SARS-CoV-2, ﬁve-week old pigs are not susceptible to infection via oral/
intranasal/intratracheal challenge. Pigs are therefore unlikely to be signiﬁcant carriers of SARS-CoV-2 and are not a suitable
pre-clinical animal model to study SARS-CoV-2 pathogenesis or eﬃcacy of respective vaccines or therapeutics.
ARTICLE HISTORY Received 17 August 2020; Revised 25 September 2020; Accepted 28 September 2020
KEYWORDS SARS-CoV-2; COVID-19; swine; coronavirus; pigs; infection models; zoonotic disease

Introduction
The emergence of the SARS-CoV-2 virus, the causative
agent of COVID-19, has resulted in a global pandemic
with over 20 million cases and 740,000 deaths as of August
13, 2020 [1,2]. SARS-CoV-2 causes a respiratory disease in
humans with a broad clinical presentation, ranging from
asymptomatic or mild illness to severe fatal disease with
multi-organ failure [3–6]. SARS-CoV-2 is rapidly transmissible via contact with infected respiratory droplets
and can also be transmitted by asymptomatic carriers
[6–8]. To curb viral spread, countries have instituted varying levels of social distancing policies, which have signiﬁcant negative economic and social impacts [9]. Mitigating
the eﬀects of this unprecedented pandemic will necessitate
the development of eﬀective vaccines and therapeutics,
which will require well-characterized and standardized
pre-clinical animal models.
SARS-CoV-2 is a member of the Betacoronavirus
genus that includes the pathogenic human viruses

SARS-CoV and MERS-CoV [2,10–12]. While details
of the origin of SARS-CoV-2 are unknown, evidence
indicates it emerged from a zoonotic spillover event,
with bats and perhaps pangolins as probable origin
species [2,13–15]. The potential for a reverse zoonotic
event, i.e. human-to-animal transmission, is possible
and of signiﬁcant concern to animal and public health
[16–18]. Instances of natural human-to-animal transmission of SARS-CoV-2 have been reported with
COVID-19 patients in domestic settings (dogs and
cats), zoos (lions and tigers), and farms (mink) [18–
20]. Therefore, investigations into the infectivity of
SARS-CoV-2 in various animal species with human
contact are essential to assess and control the risk of
a spillover event and to establish the role these animals
may play in the ecology of the virus.
Several studies have determined the susceptibility
of diﬀerent animal species to SARS-CoV-2 via experimental infection [20,21]. Cats, hamsters, and ferrets
are highly susceptible to SARS-CoV-2 infection,
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demonstrate varying clinical and pathological disease
manifestations, readily transmit the virus to naïve animals, and mount a virus-speciﬁc immune response
[22–28]. Dogs are mildly susceptible to experimental
SARS-CoV-2 infection, with limited viral replication
but with clear evidence of seroconversion in some animals [22]. Poultry species seem to be resistant to
SARS-CoV-2 infection [22,26]. These ﬁndings establish the respective utility of diﬀerent animal species
as pre-clinical models to study SARS-CoV-2.
Several lines of evidence suggest that pigs could be
susceptible to SARS-CoV-2 infection. Pigs are susceptible to both experimental and natural infection with
the related betacoronavirus, SARS-CoV, and demonstrate seroconversion [29,30]. Structure-based analyses
predict that the SARS-CoV-2 Spike (S) protein receptor
binding domain (RBD) binds the pig angiotensin-converting enzyme 2 (ACE2) entry receptor with similar
eﬃciency compared to human ACE2 [31]. Single-cell
screening also indicates that pigs co-express ACE2
and the protease TMPRSS2 (viral activating factor) in
a variety of diﬀerent cell lines, and SARS-CoV-2 replicates in various pig cell lines [2,26,32,33]. Despite these
preliminary data indicating that pigs could be susceptible to SARS-CoV-2 infection, two recent studies
revealed that intranasal inoculation of three and twelve
pigs, respectively, with 105 pfu or TCID50 of SARSCoV-2 did not lead to any detectable viral replication
or seroconversion [22,26]. However, the single route
of intranasal inoculation used in these studies suggests
that additional investigations are necessary before
deﬁnitive conclusions can be made regarding susceptibility of pigs to SARS-CoV-2.
In the present study, we determined the susceptibility of swine cell lines and domestic pigs to SARSCoV-2 infection. Two diﬀerent porcine cell lines were
found to be permissive to SARS-CoV-2 infection showing
cytopathic eﬀects (CPE). Domestic pigs were challenged
via simultaneous oral/intranasal/intratracheal inoculation
with a 106 TCID50 dose of SARS-CoV-2. SARS-CoV-2
did not replicate in pigs and none of them seroconverted.
Furthermore, the virus was not transmitted from SARSCoV-2 inoculated animals to sentinels. The present
ﬁndings, combined with the other studies [22,26],
conﬁrm that pigs seem resistant to SARS-CoV-2 infection
despite clear susceptibility of porcine cell lines. Pigs are
therefore unlikely to play an important role in the
COVID-19 pandemic as a virus reservoir or as a pre-clinical animal model to study SARS-CoV-2 pathogenesis or
develop novel countermeasures.

Materials and Methods
Virus and cells
SARS-CoV-2 USA-WA1/2020 isolate (GenBank
accession # MN985325) [34] was obtained from BEI

2279

resources (catalog # NR-52281, American Type Culture Collection [ATCC®]. Manassas, VA, USA). The
virus was passaged three times in VeroE6 cells
(ATCC® CRL-1586™), before being passaged two
times in swine testicle (ST; ATCC CRL-1746™) and
four times in porcine kidney (PK-15; ATCC® CCL33™) cell lines to investigate suitability of these
swine cell lines for propagation of SARS-CoV-2. The
ﬁrst passage of the SARS-CoV-2 virus from ST cells
was used to prepare the challenge material. The titre
of the virus inoculum stock was 2.5 × 105 TCID50/
mL All experiments involving the SARS-CoV-2 virus
were performed under Biosafety Level (BSL) 3+ conditions at the Biosecurity Research Institute (BRI)
at Kansas State University (KSU), Manhattan, KS,
USA.
Outline of animal experiments
Animal infection experiments using swine were performed under BSL-3Ag conditions at the BRI at
KSU. Animal research was conducted in compliance
with the Animal Welfare Act and other federal statutes
and regulations relating to animal care and experimentation under protocol #4390, approved by the
Institutional Animal Care and Use Committee
(IACUC) at Kansas State University on April 8, 2020.
Eighteen pigs (mix of males and females, ﬁve weeks
of age) were used in the study. Pigs were acquired
from a source guaranteed free of swine inﬂuenza
virus (SIV), porcine circovirus-2 (PCV-2), and porcine reproductive and respiratory syndrome virus
(PRRSV) infection. The study outline is illustrated in
Figure 1. Upon arrival, pigs were acclimated for 3
days prior to SARS-CoV-2 inoculation. Nine pigs
were designated as uninfected negative controls and
housed in separate BSL-2 facilities. Three of these
uninfected negative control pigs were humanely
euthanized at 3 days post challenge (DPC) to provide
negative control clinical and tissue samples. Nine
principal infected pigs were housed in the same
room in two separate groups (4 or 5 pigs each; Figure
1) and were infected with 1 x106 TCID50 of SARSCoV-2 orally (1 mL), intranasally (1 ml; 0.5 ml each
nostril) and intratracheally (2 mL), after being
anesthetized with a mixture of telazol/xylazine.
Three sentinel contact pigs were added to each
group on 1 DPC (Figure 1). Rectal temperature and
signs of clinical disease for each pig were determined
daily throughout the study; clinical signs include overall activity/attitude (signs of depression, decreased
alertness or unresponsiveness), appetite (based on
interest in treats), respiratory signs (sneezing, coughing, laboured breathing, nasal discharge), and digestive signs (diarrohea or vomiting). Blood samples
and nasal, oropharyngeal, and rectal swabs were collected in virus transport medium (VTM; DMEM
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Figure 1. Study Design. Eighteen pigs were placed into three groups. Group 1 (principal infected animals) consisted of nine pigs
(four and ﬁve in each pen) and was inoculated via intranasal (IN), oral (PO), and intratracheal (IT) routes simultaneously with a total
dose of 1 × 106 TCID50 of SARS-CoV-2 in 4 mL DMEM. The pigs in Group 2 (n = 6; sentinel contact animals) and Group 3 (n = 3;
mock control animals) were housed in a separate room. At 1-day post challenge (DPC), the six pigs in Group 2 were co-mingled
with the principal infected animals in Group 1 (three pigs per pen) and served as sentinel contact controls. The remaining three
pigs in Group 3 remained in separate housing and served as mock-infected negative controls and were euthanized and necropsied
on 3 DPC. Principal infected animals were euthanized and necropsied at 4 (n = 3), 8 (n = 3), and 21 (n = 3) DPC to determine the
course of infection. All six sentinel pigs were also euthanized on 21 DPC.

plus antibiotic/antimycotic) at 0, 1, 3, 5, 7, 10, 14, and
21 DPC. As summarized in Table 1 and Figure 1, pigs
were humanely euthanized for scheduled post mortem
examinations on 4 DPC (3 principal infected pigs), 8
DPC (3 principal infected pigs), and 21 DPC (remaining 3 principal infected and 6 sentinel pigs) to collect
respiratory tissue samples, with blood and swab
samples collected on pigs prior to euthanasia. Gross
pathological examinations on major organs were performed and respiratory tissue samples were collected
and either stored in 10% neutral-buﬀered formalin
or stored as fresh samples at −80°C. Blood and swab
samples were all ﬁltered using a 0.2 µm ﬁlter prior to
storage at −80°C.

RNA extraction and reverse transcription
quantitative PCR (RT-qPCR)
RNA was isolated from blood, swabs, and tissue
samples using a magnetic bead-based protocol in a
BSL-3+ laboratory at the BRI at KSU. Lung tissue
homogenates (200 mg per 1 mL DMEM; 20% w/v)
were prepared by thawing tissue, mincing it into
1 mm sections, followed by lysis in a 2 mL sure-lock
Table 1. Animal groups.
Group

Treatment

1
1
1
2

Principal
Principal
Principal
Sentinel

3

Mock

Pig ID#s
807, 161, 168
803, 841, 211
893, 193, 219
848, 194, 222,
851, 172, 894
201, 183, 238

Necropsy
4 DPC
8 DPC
21 DPC
21 DPC
3 DPC (not infected)

tube containing 5 mm stainless steel homogenization
beads using the TissueLyser LT (Qiagen, Germantown, MD, USA) for 30 s at 30 hz followed by 1 min
of 30 hz while keeping the sample cold. Following clariﬁcation via a 3-minute centrifugation (3,000xg; room
temperature), supernatants were mixed with an equal
volume of RLT lysis buﬀer. Blood and clinical swabs
were directly mixed with an equal volume of RLT
lysis buﬀer. Two hundred microliters of each sample
lysate were used to extract RNA using a magnetic
bead-based nucleic acid extraction kit (GeneReach
USA, Lexington, MA) on an automated TacoMiniTM
nucleic acid extraction system (GeneReach USA, Lexington, MA) according to the manufacturer’s protocol
with the following modiﬁcations: beads were added to
the sample well, followed by the sample lysate, then
200 µL molecular grade isopropanol (ThermoFisher
Scientiﬁc, Waltham, MA, USA). The last wash buﬀer
was replaced by molecular grade 200 proof ethanol
(ThermoFisher Scientiﬁc, Waltham, MA, USA).
Extraction positive controls (IDT, IA, USA; 2019nCoV_N_Positive Control, diluted 1:100 in RLT
buﬀer) and negative controls were employed.
Extracted RNA was eluted in 100 µL buﬀer.
Reverse transcription quantitative PCR (RT-qPCR)
was performed to detect viral RNA using the CDC
standard N2-based SARS-CoV-2 detection assay [35]
that was validated for use with the qScript XLT 1Step RT-qPCR ToughMix (Quantabio, Beverly, MA,
USA) on a CFX96 real-time thermocycler (Bio-Rad,
Hercules, CA, USA) using a 20 min RT step and 45
cycle qPCR in a 20 µL reaction volume. RT-qPCR
on each sample was performed in duplicate wells
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with a quantitated PCR positive control (IDT 2019nCoV–N-Positive Control, diluted 1:100) and four
non-template negative controls on every plate. A positive Ct cut-oﬀ of <37 cycles was used. A plasmid template including the SARS-CoV-2 N gene was used as a
positive PCR ampliﬁcation control. A 10-point standard curve using quantitated stock viral RNA (USAWA1/2020 isolate) was used to quantify RNA copy
number.
Gross pathology and histopathology
During post mortem examinations, the upper and
lower respiratory tract, central nervous system, lymphatic and cardiovascular systems, gastrointestinal
and urogenital systems, and integument were evaluated. Lungs were removed in toto and the percentage
of the lung surface that was aﬀected by macroscopic
lesions was estimated by a single veterinarian experienced in evaluating gross porcine lung pathology as
previously described [36,37]. Lungs were evaluated
for gross pathology such as edema, congestion, discolouration, atelectasis, and consolidation. Lung tissue
samples from right cranial, middle, and caudal lobes
were collected and either ﬁxed in 10% neutral-buﬀered
formalin for histopathological examination or frozen
at −80°C for RT-qPCR testing. Tissues were ﬁxed in
formalin for 7 days, then transferred to 70% ethanol
(ThermoFisher Scientiﬁc, Waltham, MA, USA) prior
to trimming and paraﬃn embedding following standard automated protocols used in the histology section of the Kansas State Veterinary Diagnostic
Laboratory. Following embedding, tissue sections
were cut and stained with hematoxylin and eosin
and evaluated by a board-certiﬁed veterinary pathologist who was blinded to the treatment groups.
For RNAscope® in situ hybridization (ISH), an antisense probe targeting the nucleocapsid protein (N;
nucleotide sequence 28,274-29,533) of SARS-CoV-2
USA-WA1/2020 isolate (GenBank accession #
MN985325) was designed (Advanced Cell Diagnostics
(ACD), Newark, CA, USA) and used as previously
described [38]. Four micron thick sections of formalin-ﬁxed paraﬃn-embedded tissues were mounted
on Superfrost® Plus slides (VWR, Radnor, PA). The
RNAscope® ISH assay was performed using the RNAscope 2.5 LSx Reagent Kit (ACD) on the automated
BOND RXm platform (Leica Biosystems, Buﬀalo
Grove, IL, USA). Brieﬂy, sections were subjected to
automated baking and deparaﬃnization followed by
heat-induced epitope retrieval (HIER) using an
EDTA-based solution (pH 9.0; Leica Biosystems) at
100°C for 15 min. Tissue sections were then protease
treated with RNAscope® 2.5 LSx Protease for 15 min
at 40 °C followed by hydrogen peroxide treatment
for 10 min at room temperature. Slides were incubated
with the probe mixture for 2 h at 40 °C, and the signal
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was ampliﬁed using a speciﬁc set of ampliﬁers (AMP1
through AMP6) as recommended by the manufacturer. The signal was detected using a Fast-Red solution for 10 min at room temperature. Slides were
counterstained with a ready-to-use hematoxylin for
5 min, followed by ﬁve washes with 1X BOND Wash
Solution (Leica Biosystems). Slides were ﬁnally rinsed
in deionized water, dried in a 60 °C oven for 30 min,
and mounted with Ecomount® (Biocare, Concord,
CA, USA). Lung sections from a SARS-CoV-2infected hamster were used as positive assay controls.
For immunohistochemistry (IHC), four micron
thick sections of formalin-ﬁxed paraﬃn-embedded
tissue were mounted on Superfrost® Plus slides and
subjected to IHC using a SARS-CoV-2-speciﬁc antinucleocapsid rabbit polyclonal antibody (rabbit antibody #3A, developed by our laboratory) with the
method previously described [38]. IHC was performed
using the automated BOND-RXm platform and the
Polymer Reﬁne Red Detection kit (Leica Biosystems).
Following automated deparaﬃnization, HIER was
performed using a citrate-based solution (pH 6.0;
Leica Biosystems) at 100 °C for 20 min. Sections
were then incubated with the primary antibody
(1:5,000 in primary antibody diluent [Leica Biosystems]) for 30 min at room temperature, followed by
a polymer-labeled goat anti-rabbit IgG coupled with
alkaline phosphatase (30 min). Fast Red was used as
the chromogen (15 min), and counterstaining was
performed with hematoxylin for 5 min. Slides were
dried in a 60 °C oven for 30 min and mounted with
a permanent mounting medium (Micromount®,
Leica Biosystems). Lung sections from a SARS-CoV2-infected hamster were used as positive assay
controls.
Serological testing
To detect SARS-CoV-2 antibodies in sera, indirect
ELISAs were performed using recombinant SARSCoV-2 Receptor Binding Domain (RBD) expressed
in HEK cells with a C-terminal Strep-tag and the
Nucleocapsid (N) protein expressed in E.coli with a
C-terminal His-tag. Brieﬂy, the recombinant proteins
were produced in their respective expression systems
according to standard procedures and puriﬁed using
either Ni-NTA (ThermoFisher Scientiﬁc, Waltham,
MA, USA) or Strep-Tactin (IBA Lifesciences, Goettingen, Germany) columns according to manufacturer’s
instructions. For testing, 96-well plates were coated
with 100 ng of the recombinant protein in 100 µL of
sodium carbonate/bicarbonate buﬀer and incubated
overnight at 4°C. The wells were then washed and
blocked with casein blocking buﬀer. Sera were diluted
1:200 in 100 µL of casein blocking buﬀer, incubated at
room temperature for 1 h, then washed with washing
solution. One hundred microliters of anti-pig-IgG or
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IgM secondary antibodies, conjugated with horseradish peroxidase, and diluted 1:2,500 in blocking
buﬀer were then incubated at room temperature for
1 h, protected from light. TMB colorimetric substrate
was added and incubated at room temperature for 5
min, then the reaction was stopped with a solution
of 0.2 sulfuric acid. The optical density (OD) value
was measured at 450 nm within 5 min of adding the
stop solution to quantify the amount of antigen-binding antibody present in the sample. Sera from mockinfected pigs were used as negative controls. Sera collected from SARS-CoV-2 infected cats, from a diﬀerent study [39], were used as positive controls. Serum
from pigs infected with African Swine Fever Virus
(ASFV) and the baculovirus-expressed ASFV-p54
antigen were used as positive control for anti-pigIgG or IgM antibodies. The cutoﬀ for a sample being
called positive was deﬁned by the average OD at 0
DPC +3x standard deviation.
The presence of virus-neutralizing antibodies in
sera was determined via microneutralization assay.
Serum samples were diluted 1:10 and heat-inactivated
at 56°C for 30 min while shaking. Subsequently,
100 µL of serum samples per well in duplicate were
subjected to 2-fold serial dilutions starting at 1:20
through 1:2560 in 100 µL culture media. One hundred
microliters of 100 TCID50 of SARS-CoV-2 was then
added to 100 µL of the sera dilutions and incubated
for 1 h at 37°C, followed by culture of the mixture
on VeroE6 cells in 96-well plates. Results of the virus
neutralization were determined by the appearance of
CPE, which was observed under a microscope at 96
h post inoculation. The neutralizing antibody titre is
determined as the reciprocal of the average serum
dilution at which no CPE breakthrough in any of the
testing wells is observed. Neutralizing sera from
SARS-CoV-2-infected cats from a separate study
[39] were used as positive controls.

sequence (Genbank accession # MN985325) [34] to
generate a consensus sequence.

Results
Propagation of SARS-CoV-2 in swine cells
The SARS-CoV-2 USA-WA1/2020 isolate, which was
isolated from a human patient in Washington State,
USA, was used as the parent stock for the study [34].
The virus stock was passaged 3 times at a multiplicity
of infection (MOI) between 0.001 and 0.01 in VeroE6
cells and NGS sequenced before being inoculated onto
porcine cells. The consensus sequence of the VeroE6passaged virus was 100% identical to the GenBank
reference
sequence
(GenBank
accession
#
MN985325). To determine the susceptibility of porcine cell lines to SARS-CoV-2 infection, swine testicle
(ST) and porcine kidney (PK-15) cell lines were inoculated with approximately 0.05 MOI of passage 3 of the
VeroE6-passaged SARS-CoV-2 USA-WA/1/2020 isolate. No obvious cytopathic eﬀect (CPE) was observed
in either cell line during the ﬁrst passage, however
clear CPE was observed in passage two in ST cells
and passage four in PK-15 cells (Figure 2). Cell culture
supernatant from SARS-CoV-2 passage one and two
on ST cells, and passage three on PK-15 cells was collected, and RNA extracted for sequencing. Next generation sequencing was performed to generate a
consensus genomic sequence for the ST- and PK-15passaged SARS-CoV-2 virus. No nucleotide mutations
or amino acid substitutions within the consensus
sequence were observed upon passage in the two porcine cell lines. These results indicate that SARS-CoV2 is able to infect porcine kidney and testicle cells without the requirement of major genetic adaptations in the
consensus sequence. SARS-CoV-2 from passage 1 in ST
cells was used as challenge material for the pig inoculation since a suﬃcient volume and titre was available
only from passage 1 at the time of challenge.

Next generation sequencing
To determine the consensus sequence of the USAWA/1/2020 virus and to analyse if there were any
nucleic acid substitutions in the SARS-CoV-2 virus
consensus sequence after passage in porcine cell
lines, RNA was extracted from cell culture supernatant
as described above. The RNA was then subjected to
RT–PCR ampliﬁcation using a tiled-primer approach
to amplify the entire SARS-CoV-2 genome as
described previously [40]. Brieﬂy, the PCR amplicons
were pooled and subjected to library preparation for
Next Generation Sequencing using the Nextera XT
library prep kit (Illumina, San Diego, CA, USA). The
library was normalized and sequenced using a MiSeq
nano v2 2 × 250 sequencing kit. The sequence was
then analysed by mapping reads to the parent

Oral/intranasal/intratracheal inoculation of
pigs with SARS-CoV-2
To determine the eﬀect of SARS-CoV-2 infection in
domestic pigs, nine ﬁve-week-old SARS-CoV-2 seronegative piglets were inoculated with a total of 1 ×
106 TCID50 of the USA-WA1/2020 isolate, which
was passaged once in swine ST cells (Figure 1). The
challenge material (total 4 mL) was administered
orally (1 mL), intranasally (1 mL; 0.5 mL each nostril)
and intratracheally (2 mL) after sedation of the animals. At 1-day post challenge (DPC), six uninoculated
sentinel contact pigs were co-mingled with the principal inoculated animals (3 animals per pen). Daily rectal temperatures were recorded for each pig and
clinical signs were monitored daily, including
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Figure 2. Cytopathic eﬀect (CPE) of SARS-CoV-2 in Swine Testicle (ST) and Porcine Kidney (PK-15) cells. SARS-CoV-2 USA-WA1/
2020 isolate was passaged in ST and PK-15 porcine cells. Passage two in ST cells (B) and passage four in PK-15 cells (C) resulted
in clear CPE, similar to that observed in permissive VeroE6 cells (A). No CPE is observed in the uninfected VeroE6 or porcine cells
lines (D, E, F).

observations for signs of lethargy, hyporexia, respiratory distress (coughing, laboured breathing, nasal discharge), and digestive issues (diarrohea or vomiting).
No signiﬁcant change in rectal temperature was
observed in the principal inoculated nor sentinel contact pigs throughout the study (Figure 3). Moreover,
no obvious clinical signs were observed for any of
the principal inoculated nor sentinel pigs throughout
the 21-day observation period.
To detect viral replication in the principal and sentinel pigs, clinical samples were subjected to RT-qPCR

to detect the SARS-CoV-2 N gene (Table 2) [35].
Blood, as well as oropharyngeal, nasal, and rectal
swabs, were collected at various time points throughout the study and upper and lower respiratory tract
tissues were collected at post-mortem examinations
on 4, 8 and 21 DPC. RT-qPCR failed to detect any
viral RNA in any swab or blood sample for the duration of the study (Table 2). The only exception was
a nasal swab sample at 1 DPC in the principal inoculated pig #161, for which one of two RT-qPCR replicates yielded a low ﬂuorescent ampliﬁcation curve

Figure 3. Average daily rectal temperatures of SARS-CoV-2 inoculated and sentinel pigs. Daily average rectal temperatures of pigs
inoculated orally, intranasally, and intratracheally with SARS-CoV-2 (red) and co-mingled sentinel pigs (green) showed no signiﬁcant change over the course of the experiment. The baseline temperature (blue; 39.6°C to 40.4°C) was determined from all pigs
before infection.
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Table 2. Summary of RT-qPCR results.
Group

Nasal
Swabs

Oropharyngeal
Swabs

Rectal
Swabs

Blood

Lung

-*
Inoculated1
Sentinel2
Uninfected3
(-) = negative
1
Swabs/blood were tested on 0, 1, 3, 5, 7, 10, and 14 DPC. Lung tissue was
collected 4, 8, and 21 DPC.
2
Swabs/blood were tested on 0, 3, 5, and 10 DPC. Lung tissue was collected on 21 DPC
3
Swabs/blood were tested on 0 DPC. Lung tissue was collected on 3 DPC
for these uninfected controls.
*One pig (#161) had a ct signal of 37.72 (3.82 × 104 copy number/mL) for 1
out of 2 of RT-qPCR wells on 1 DPC. This is considered a negative result
above the Ct cut-oﬀ of >37.

with a Ct of 37.72, which is slightly above the Ct cutoﬀ of >37 and thus considered a negative sample
(Table 2). Moreover, viral RNA was not detected in
any lung sample collected at post-mortem examination
on 4, 8 and 21 DPC (Table 2). In addition, gross and
histopathological analysis of lung from the principal
challenged pigs, including immunohistochemical and
in situ hybridization analyses speciﬁc for the SARSCoV-2 nucleocapsid (N) protein, did not reveal the
presence of any obvious pathological lesions or the
presence of SARS-CoV-2 antigen or RNA (Table 3,
Figure 4). These results indicate that SARS-CoV-2
failed to replicate in the respiratory and digestive
tract as well as the blood in orally/intranasally/intratracheally inoculated pigs throughout an observation
period of 21 days. This is conﬁrmed by the fact that
the principal infected pigs failed to transmit SARSCoV-2 to co-mingled sentinel animals.
Absence of immune response in SARS-CoV-2inoculated pigs
To determine whether the orally/intranasally/intratracheally inoculated pigs developed an immune
response against SARS-CoV-2 antigens, sera collected
from infected pigs at various time points post infection
were subjected to indirect ELISAs to detect IgG and
IgM antibodies reactive against the receptor-binding
domain (RBD) of the SARS-CoV-2 spike protein
and the SARS-CoV-2 nucleocapsid (N) protein.
Cumulatively, the results from these assays indicated
that the infected pigs did not develop an IgG or IgM
immune response against either of the SARS-CoV-2
antigens at any point throughout the study (Figure 5).
The sera from one sentinel pig (#894) showed
Table 3. Macroscopic lesions of total lung (%).
Group

Day of Necropsy

Inoculated

4 DPC
8 DPC
21 DPC
All pigs
21 DPC
3 DPC

Sentinels
Uninfected

Average Score
1.6
1.1
2.9
1.9
3.4
0.1

transient IgM reactivity on 3 and 5 DPC against N
and RBD and an isolated IgG reactivity against N
and RBD on 3 DPC. Importantly, neutralizing antibody experiments performed with sera collected
from principal inoculated and sentinel contact pigs
necropsied at 14 and 21 DPC, revealed that none of
the pigs developed neutralizing antibodies against
SARS-CoV-2. Overall, these results indicate that
SARS-CoV-2 is unable to replicate and generate an
immune response in pigs upon oral/intranasal/intratracheal inoculation. In addition, transmission to sentinel contact animals was not possible.

Discussion
SARS-CoV-2 is a zoonotic agent, and a detailed
understanding of the susceptibility of various animal
species to SARS-CoV-2 is central to controlling its
spread [16,17]. In addition, the development of animal
models that emulate COVID-19 in humans is essential
for pre-clinical testing of novel vaccines and therapeutics [20]. In this study, we inoculated nine pigs
with a high dose of SARS-CoV-2 that was passaged
once in porcine cells. Simultaneous oral/intranasal/
intratracheal inoculation did not result in any detectable viral RNA in the blood, the oral/nasal/rectal cavities, or the lungs. Also, none of the co-mingled,
sentinel contact pigs shed viral RNA. Moreover, a
virus-speciﬁc immune response characteristic of
SARS-CoV-2 infection was not observed within the
21-day study period in the principal infected or sentinel pigs. The transient nature of the IgM and IgG
response observed in pig #848, particularly against
the N protein, could indicate cross-reactivity of antibodies directed against another porcine coronavirus
such as porcine epidemic diarrohea virus (PEDV),
transmissible gastroenteritis virus (TGEV), or porcine
respiratory coronavirus (PRCV) [41–43]. A two-way
antigenic cross-reactivity between SARS-CoV and
TGEV/PRCV has been documented previously and
attributed speciﬁcally to the N protein, which is 90%
identical between SARS-CoV and SARS-CoV-2 [44–
46]. Such antibodies could be maternally derived and
therefore transient as the lack of SARS-CoV-2 speciﬁc
reactivity by the end of the study might suggest. In
contrast to previous SARS-CoV-2 swine studies
[22,26], the present study used a more stringent inoculation procedure (intratracheal and oral, in addition to
intranasal) and a 1 log higher titre of virus inoculum
(106 vs 105). In addition, the inoculum in the present
study was passaged once in porcine ST cells. These
results, combined with previous intranasal pig inoculation studies [22,26], indicate that young pigs seem to
be resistant to SARS-CoV-2 infection, are unlikely to
be a SARS-CoV-2 carrier animal species, and are
also not suitable as an animal model for COVID-19
research.
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Figure 4. Histopathological analysis of pig lung tissue. Lung tissue sections were stained with hematoxylin and eosin for histopathological evaluation (H&E, left panels). Immunohistochemistry (IHC, middle panels) analysis was done using a rabbit anti-SARSCoV-2 nucleocapsid polyclonal antibody and in situ hybridization (ISH, right panels) analysis using an anti-sense probe to detect
nucleocapsid-speciﬁc RNA. (A) Uninoculated negative control pig #210, (B) SARS-CoV-2-inoculated pig #161, 4 DPC, (C) SARS-CoV2-inoculated pig #803, 8 DPC, (D) SARS-CoV-2-inoculated pig #193, 21 DPC. No signiﬁcant histopathology and no detection of
SARS-CoV-2 antigen or RNA were observed by IHC or ISH. Lung sections from a SARS-CoV-2-infected hamster were used as positive
assay controls for ISH and IHC (data not shown). Magniﬁcation is 10x for all images.

The results of the present and previous SARS-CoV2 inoculation studies in pigs are intriguing in light of
the ﬁndings that the porcine ACE2 receptor seems
highly compatible with the SARS-CoV-2 RBD,
suggesting that pigs could be susceptible to SARSCoV-2 infection [2,31]. Pigs are susceptible to both
experimental and natural infection with SARS-CoV
[29,30]. However, the experimental SARS-CoV infection was via simultaneous intranasal/oral/intraocular/
intravenous inoculation [29], thus the actual route(s)

of SARS-CoV infection cannot be determined.
Recently, several porcine cell lines have been shown
to be permissive to SARS-CoV-2 infection [26,33]; in
addition, single-cell screening studies showed that
porcine ACE2/TMPRSS2 expression are compatible
with infection [32]. In contrast to previous reports
that some porcine cell lines are susceptible to SARSCoV-2 infection, but show no CPE [26,33], we
found that both ST and PK-15 cell lines are susceptible
to infection and observed CPE after two or four
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Figure 5. Serological response in pigs infected orally/intranasally/intratracheally with SARS-CoV-2 and sentinel contact pigs. Indirect ELISAs were performed against the SARS-CoV-2 antigens N (nucleocapsid protein [A, B]) and RBD (Spike protein receptor binding domain [C, D]) to detect antigen-speciﬁc IgG (A, C) or IgM (B, D) antibodies. Sera reactivity was determined for three principal
infected pigs (#893 (red), #193 (dark red), #219 (orange)) and three sentinel pigs (#848 (blue), #172 (cyan), #894 dark blue)). The
cutoﬀ for a positive sample was determined by +3 standard deviations of 0 DPC samples (dotted line). Feline SARS-CoV-2-speciﬁc
antibodies were used as positive controls from a separate study (left bar, [38]). Porcine positive control sera for IgG/IgM-speciﬁc
antibodies were ASFV-infected pig sera detecting the ASFV-p54 antigen (right bar). Uninfected pigs were used as negative controls. O.D. – optical density.

passages, respectively. The delay in observed CPE until
after several passages is likely due to the lower susceptibility of swine cells to the virus compared to VeroE6,
combined with the low MOI used for the ﬁrst blind
passage (0.05 MOI). The absence of SARS-CoV-2
replication and transmission in the present and two
previous pig studies [22,26] seems to lessen the need
to monitor pig populations for SARS-CoV-2 during
the ongoing pandemic. However, the evidence
described above suggesting pig susceptibility should
not be disregarded, because all pig studies to date
have used rather young and healthy pigs, and commercially available pig breeds/genetics; increased age,
diﬀerent breeds, or co-morbidities could make pigs
more susceptible to infection. We also have to be
aware that unforeseen genetic changes in the SARSCoV-2 genome may result in a better compatibility
of the virus for pigs in the future.
Pigs are considered to be an excellent model for
studying human infectious diseases based on their
relatedness to humans in terms of anatomy and
immune responses and they have been found to be
much more predictive for the eﬃcacy of therapeutics
when compared to rodent models [47]. However, the

results presented here indicate that pigs are not a suitable preclinical model for SARS-CoV-2 pathogenesis
studies and the development and eﬃcacy testing of
therapeutics and/or vaccines. A recently available
article indicates that while pigs are not susceptible to
SARS-CoV-2 infection, neutralizing antibody
responses were detected in pigs infected via intramuscular or intravenous inoculation routes [48]; this indicates that pigs could be used for immunogenicity
studies related to SARS-CoV-2. However, the use of
pigs to monitor for SARS-CoV-2 immune responses
must be carefully planned to avoid detection of
cross-reactive antibodies speciﬁc for porcine coronaviruses [43]. Alternate pre-clinical animal models,
namely non-human primates, Syrian hamsters, transgenic or transduced mice expressing human ACE2,
ferrets, or even cats need to be considered to gain
additional insights into SARS-CoV-2 pathogenesis
and virulence. Comprehensive characterization of
SARS-CoV-2 pathogenesis in pre-clinical animal
models and the establishment of standardized infection and testing protocols will be crucial for the development of much-need countermeasures to combat
COVID-19.
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